Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy

• Main Authors: Chen Hu (Author), Lijuan Shen (Author), Fengming Zou (Author), Yun Wu (Author), Beilei Wang (Author), Aoli Wang (Author), Chao Wu (Author), Li Wang (Author), Jing Liu (Author), Wenchao Wang (Author), Qingsong Liu (Author)
• Format: Book
• Published: Elsevier, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abnormally activated CDK9 participates in the super-enhancer mediated transcription of short-lived proteins required for cancer cell survival. Targeting CDK9 has shown potent anti-tumor activity in clinical trials among different cancers. However, the study and knowledge on drug resistance to CDK9 i...